Algert Global LLC Has $2.73 Million Stake in Omnicell, Inc. $OMCL

Key Points

• Algert Global LLC significantly increased its holdings in Omnicell, Inc. by 278.0%, owning approximately $2.73 million worth of shares as of the last quarter.
• Institutional investors now hold 97.70% of Omnicell's stock, with notable increases in positions by several firms, including Dimensional Fund Advisors, which boosted its holdings by 31.6%.
• Omnicell has received mixed analyst ratings, with recent price targets ranging from $34.00 to $62.00, and current consensus rating being a "Moderate Buy".

Algert Global LLC lifted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 278.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 78,032 shares of the company's stock after acquiring an additional 57,390 shares during the quarter. Algert Global LLC owned 0.17% of Omnicell worth $2,728,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Redmond Asset Management LLC grew its stake in Omnicell by 16.4% in the first quarter. Redmond Asset Management LLC now owns 141,111 shares of the company's stock worth $4,933,000 after purchasing an additional 19,902 shares in the last quarter. Liontrust Investment Partners LLP grew its stake in Omnicell by 7.3% in the first quarter. Liontrust Investment Partners LLP now owns 175,655 shares of the company's stock worth $6,141,000 after purchasing an additional 11,981 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in Omnicell in the first quarter worth about $448,000. Public Sector Pension Investment Board grew its stake in Omnicell by 27.6% in the first quarter. Public Sector Pension Investment Board now owns 146,916 shares of the company's stock worth $5,136,000 after purchasing an additional 31,765 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Omnicell in the first quarter worth about $6,218,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Performance

Shares of NASDAQ OMCL traded down $0.37 during midday trading on Tuesday, hitting $32.72. 518,015 shares of the company's stock were exchanged, compared to its average volume of 640,904. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The stock's 50 day moving average price is $29.78 and its 200-day moving average price is $31.74. The firm has a market cap of $1.50 billion, a P/E ratio of 65.44, a PEG ratio of 7.23 and a beta of 0.78. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The firm's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on OMCL shares. Piper Sandler decreased their price target on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Wall Street Zen downgraded Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Bank of America lifted their target price on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Finally, Wells Fargo & Company lifted their target price on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.